Hepatitis C Virus: No Longer a Barrier to Oncology Care
- PMID: 30676362
- DOI: 10.14309/ajg.0000000000000095
Hepatitis C Virus: No Longer a Barrier to Oncology Care
Abstract
Historically, hepatitis C virus infection has posed a barrier to cancer therapies and enrollment in clinical trials for oncology patients. Oral direct acting antivirals now allow most patients, previously considered difficult to treat to be effectively (>95% sustained virologic response) and safely cured.
Comment on
-
Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.Am J Gastroenterol. 2019 Feb;114(2):250-257. doi: 10.1038/s41395-018-0383-2. Am J Gastroenterol. 2019. PMID: 30410039
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical